Source: Google NewsPublished on 2022-08-04
Related Articles:
- Aptinyx to Launch Phase 2 Study of NYX-458 to Treat Cognitive Impairment May 20, 2019 Positive preclinical and Phase 1 clinical data support further assessmentof Aptinyx‘s investigational compound NYX-458 for the treatment of cognitive impairment associated with Parkinson’s disease in new Phase 2 studies. Aptinyx expects to launch a new Phase 2 clinical study in Parkinson’s patients this year, the company announced in a press release. “So far, 2019 has been marked by the achievement of…
- Enrollment in Phase 2 Study of Cognitive Treatment Paused for Pandemic May 19, 2020 Aptinyx has paused patient enrollment in its Phase 2 trial evaluating NYX-458 to treat mild cognitive impairment in people with Parkinson’s disease due to the current COVID-19 pandemic. The decision was made in light of the elevated risk this virus poses to an older patient population, and the challenges in assessing changes in cognitive skills remotely. “In the midst of the…
- Aptinyx’s Investigational Parkinson’s Therapy NYX-458 Enters Phase 1 Clinical Testing August 7, 2018 Aptinyx has launched a Phase 1 clinical trial of NYX-458, a potential treatment for cognitive impairment in Parkinson’s disease patients. The randomized, double-blind, placebo-controlled trial will be conducted in roughly 62 healthy volunteers to evaluate the safety, tolerability, and pharmacokinetics of the compound. Pharmacokinetics refers to a drug’s absorption, bioavailability, distribution, metabolism, and excretion in the body. Patients will receive both…
- Oral Treatment in Phase 2 Trial, NYX-458, Seen to Aid Cognition in Primate Model Study February 5, 2020 Aptinyx‘s investigational oral compound NYX-458 was able to ease cognitive difficulties in a non-human primate model of Parkinson’s disease, including attention, working memory and executive thinking, a study reports. Its findings also suggest that NYX-458 — now in a Phase 2 clinical trial (NCT04148391) enrolling patients across the U.S. — does not interfere with levodopa treatment. The study, “NYX‐458 improves cognitive…
- Oral Treatment in Phase 2 Trial, NYX-458, Seen to Aid Cognition in Primate Model Study February 5, 2020 Aptinyx‘s investigational oral compound NYX-458 was able to ease cognitive difficulties in a non-human primate model of Parkinson’s disease, including attention, working memory and executive thinking, a study reports. Its findings also suggest that NYX-458 — now in a Phase 2 clinical trial (NCT04148391) enrolling patients across the U.S. — does not interfere with levodopa treatment. The study, “NYX‐458 improves cognitive…
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- Phase 2 Study to Evaluate Possible Oral Treatment for Mild Cognitive Impairment in Parkinson’s December 9, 2019 Aptinyx will soon open a Phase 2 clinical study of NYX-458, a potential oral treatment of mild cognitive impairment (MCI) associated with Parkinson’s disease (PD). Although the main features of Parkinson’s involve difficulties with mobility and motor function, many patients also experience non-motor symptoms that include cognitive problems, for which few options exist. Parkinson’s is a progressive disease of the nervous system, but…
- Monthly Research Review – May 2021 May 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during May 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Monthly Research Review: Jaunary 2020 January 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
- Aptinyx : Reports Second Quarter 2022 Financial Results and Recent Highlights - Form 8-K - Marketscreener.com August 4, 2022 Aptinyx : Reports Second Quarter 2022 Financial Results and Recent Highlights - Form 8-K Marketscreener.com
- Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - Business Wire March 24, 2021 Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Business Wire
- Aptinyx Reports Second Quarter 2019 Financial Results and Highlights - GlobeNewswire August 12, 2019 Aptinyx Reports Second Quarter 2019 Financial Results and Highlights GlobeNewswireReported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study. On track to initiate three additional Phase 2 studies in 2H 2019 ...
- 7 Legal and Financial Tips to Plan a Better Life with Parkinson’s March 5, 2019 The first concern for most people following a Parkinson’s disease (PD) diagnosis is to get the right medical help. Next, many people begin planning for living their life with Parkinson’s ensuring that their legal, financial and insurance concerns are all in good shape. While earning ability or other sources of cash flow may change, with planning and a better understanding of the…
- Monthly Research Review: January 2022 January 31, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
- Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights - Yahoo Finance August 4, 2022 Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights Yahoo Finance
- Monthly Research Review – November 2019 November 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Aptinyx to Report Second Quarter 2019 Financial Results on Monday, August 12, 2019 - Yahoo Finance August 5, 2019 Aptinyx to Report Second Quarter 2019 Financial Results on Monday, August 12, 2019 Yahoo FinanceEVANSTON, Ill., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for ...
- Monthly Research Review – December 2021 December 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update - GlobeNewswire May 14, 2019 Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswireFour Phase 2 studies expected to be ongoing by year end; multiple data read-outs anticipated in 2019 and 2020. Management to host conference call today at ...
- Monthly Research Review – October 2021 October 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Monthly Research Review – February 2022 February 28, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2022. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress - Business Wire August 3, 2021 Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress Business Wire